Hologic, Inc. (HOLX) Forecasted to Earn FY2018 Earnings of $2.23 Per Share

Hologic, Inc. (NASDAQ:HOLX) – Investment analysts at William Blair upped their FY2018 earnings per share estimates for shares of Hologic in a research note issued on Thursday. William Blair analyst B. Weinstein now anticipates that the medical equipment provider will post earnings per share of $2.23 for the year, up from their previous estimate of $2.12. William Blair also issued estimates for Hologic’s FY2019 earnings at $2.49 EPS.

HOLX has been the topic of several other reports. Needham & Company LLC reiterated a “buy” rating and set a $50.00 price objective (up from $48.00) on shares of Hologic in a research report on Tuesday, January 9th. Deutsche Bank lowered Hologic from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a research report on Friday, January 19th. BidaskClub lowered Hologic from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th. Cowen upgraded Hologic to a “buy” rating and set a $52.00 price objective on the stock in a research report on Wednesday, December 20th. Finally, Bank of America upgraded Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price objective on the stock in a research report on Thursday, January 4th. One analyst has rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $48.36.

Hologic (NASDAQ HOLX) opened at $37.75 on Monday. The firm has a market capitalization of $10,438.97, a PE ratio of 18.42, a price-to-earnings-growth ratio of 1.71 and a beta of 0.77. The company has a quick ratio of 0.98, a current ratio of 1.25 and a debt-to-equity ratio of 0.87. Hologic has a one year low of $35.33 and a one year high of $46.80.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.05. The business had revenue of $791.10 million for the quarter, compared to analyst estimates of $785.80 million. Hologic had a return on equity of 20.07% and a net margin of 34.53%. The company’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.52 EPS.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Grove Bank & Trust grew its position in Hologic by 115.8% during the 3rd quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock worth $105,000 after acquiring an additional 1,535 shares during the last quarter. Hall Laurie J Trustee grew its position in Hologic by 10.2% during the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after acquiring an additional 225 shares during the last quarter. MPS Loria Financial Planners LLC bought a new position in Hologic during the 2nd quarter worth approximately $191,000. NuWave Investment Management LLC bought a new position in Hologic during the 4th quarter worth approximately $199,000. Finally, National Asset Management Inc. bought a new position in Hologic during the 2nd quarter worth approximately $203,000. Institutional investors and hedge funds own 93.84% of the company’s stock.

In related news, VP Karleen Marie Oberton sold 1,023 shares of the firm’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $39.84, for a total transaction of $40,756.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.88% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.americanbankingnews.com/2018/02/12/hologic-inc-holx-forecasted-to-earn-fy2018-earnings-of-2-23-per-share.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply